YM Bioscience stock surged in after hours trading following their presentation of results from an ongoing multi-center Phase I/II study of the JAK1/2 inhibitor CYT387 for the treatment of Myelofibrosis.
After much anticipation, BioSante Pharma $BPAX released top-line data for the two pivotal phase 3 efficacy data for LibiGel, a testosterone gel for the treatment of hypoactive sexual desire disorder.
ASH Update: Incyte’s JAK1/2 Inhibitor By Patrick Crutcher and Jason Chew On Saturday December 10, we took to the floors of the San Diego Convention Center for the opening rounds.
Spectrum Pharma $SPPI shares were lower by as much as 10% on Friday 12/9/2011 based on concerns over potential generic competition for their cancer drug Fusilev (levoleucovorin). A flurry of.
PCYC: Update- Pharmacyclics Signs Worldwide Development Deal With Janssen Biotech On December 8, 2011, Pharmacyclics announced it had entered into an agreement to jointly develop its lead BTK inhibitor PCI-32765.
Achillion: Initiating Coverage Background: Achillion is a small biotech focused on the development of a cure for Hepatitis C. It has several compounds in its pipeline, all unpartnered. The two.
ArQule Inc.(NASDAQ: ARQL) is a mid-stage small molecule drug company that specializes in the development of tyrosine kinase inhibitors(TKIs). Their in-house drug development program, ArQule Kinase Inhibitor Platform (AKIP™), produced.
Does Acquisition Of Pharmasset Make Gilead A Growth Stock Again? Gilead stock has been stagnant for years as growth in its core HIV franchise has slowed. Acquisitions out designed to.
Pharmasset Stock Falling- How to Play It Pharmasset (VRUS) stock has fallen steadily since November 21st when the company announced it had decided to sell itself to Gilead (GILD) for.
This post is meant to highlight some of the key data that is expected by year’s end 2011. We have highlighted some of those catalysts which should have a significant.
Incyte Corp: Stock Running Ahead Of ASH Despite today’s slight pull-back, Incyte stock is finally making a comeback. It appears the company’s discussions at the November 29th Piper Jaffray Healthcare.
This post is meant to highlight some of the key regulatory decisions that are expected by year’s end 2011. We have highlighted some of those catalysts which should have a.
In the past week Bristol Myers Squibb (NYSE:BMY) and Pfizer (NYSE:PFE) have had two notably regulatory events for Apixiban, or ELIQUIS. On November 25th, the National Institute for Health.
Yesterday, we saw Momenta Pharmaceuticals (NASDAQ: MNTA) gain 12% on above average volume following some subtle court news that was not picked up by any news providers. Following Momenta’s win.
YM Biosciences- A Quick Take Tuesday, November 22 saw some wild moves in this stock, which plunged close to 38% in early afternoon trading before recovering for a 9.4% loss on the day. An.
Background: The market for anti-thrombosis agents is set for dramatic changes. A thrombus is an aggregation of platelets which plays a key part in several life-threatening diseases, such as myocardial.
We got a chance over the past weekend to update the clinical database. After doing so, we felt the need to quickly highlight some potential catalysts. These events are likely.
Gilead To Acquire Pharmasset For $11 Billion Gilead has agreed to buy HCV drug developer Pharmasset Inc. for $11 billion in cash. The deal calls for payment of $137 per.
Incyte Receives Approval For JAK Inhibitor In Myelofibrosis Following a trend begun earlier this year, the FDA skipped ODAC and approved another innovative cancer drug before its PDUFA date. Incyte’s.